Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
$12.89
+0.6%
$12.96
$10.95
$13.42
N/AN/A103,330 shs45,023 shs
Bionomics Limited stock logo
BNOEF
Bionomics
$0.00
-43.3%
$0.00
$0.00
$0.06
$4.45M1.86140,299 shs22,900 shs
Meta Platforms, Inc. stock logo
META
Meta Platforms
$481.73
+0.1%
$494.81
$207.13
$531.49
$1.23T1.217.16 million shs17.23 million shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$3.54
+3.2%
$2.10
$0.72
$3.69
$142.06M1.29303,820 shs325,847 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
+0.62%+1.58%0.00%+5.92%+13.57%
Bionomics Limited stock logo
BNOEF
Bionomics
0.00%0.00%0.00%0.00%-77.33%
Meta Platforms, Inc. stock logo
META
Meta Platforms
+0.14%-3.70%-5.47%+25.06%+126.28%
Rezolute, Inc. stock logo
RZLT
Rezolute
+3.21%+14.94%+77.00%+247.06%+85.34%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/AN/AN/AN/AN/AN/A
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/AN/AN/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
4.0494 of 5 stars
2.55.01.70.01.93.33.1
Rezolute, Inc. stock logo
RZLT
Rezolute
2.9302 of 5 stars
3.53.00.00.03.14.20.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/AN/A
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
2.93
Moderate Buy$520.288.00% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
3.00
Buy$8.80148.59% Upside

Current Analyst Ratings

Latest BNOEF, BGT, RZLT, META, and TLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$550.00
4/22/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/22/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$575.00 ➝ $555.00
4/18/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$535.00 ➝ $590.00
4/18/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$7.00
4/18/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/17/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$580.00 ➝ $610.00
4/17/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$525.00 ➝ $550.00
4/16/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$530.00 ➝ $610.00
4/16/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$527.00 ➝ $588.00
4/15/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$500.00 ➝ $555.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
$39.39MN/AN/AN/AN/AN/A
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
$134.90B9.10$19.75 per share24.39$60.08 per share8.02
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$3.15 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/A0.00N/AN/AN/AN/AN/A
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/A0.00N/AN/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
$39.10B$14.9032.3320.721.2228.98%29.48%19.54%4/24/2024 (Confirmed)
Rezolute, Inc. stock logo
RZLT
Rezolute
-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)

Latest BNOEF, BGT, RZLT, META, and TLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2024N/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
$4.27N/A-$4.27N/AN/AN/A    
2/13/2024Q2 2024
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.27-$0.27N/A-$0.27N/AN/A
2/1/2024Q4 2023
Meta Platforms, Inc. stock logo
META
Meta Platforms
$4.82$5.33+$0.51$5.33$39.12 billion$40.11 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
$1.3910.78%+12.82%N/A2 Years
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
$2.000.42%N/A13.42%N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A

Latest BNOEF, BGT, RZLT, META, and TLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/1/2024
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
Monthly$0.1210.98%4/12/20244/15/20244/30/2024
3/1/2024
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
Monthly$0.1211.07%3/14/20243/15/20243/28/2024
2/1/2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
quarterly$0.500.51%2/21/20242/22/20243/26/2024
2/1/2024
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
Monthly$0.1211.65%2/14/20242/15/20242/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/A
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
0.12
2.67
2.67
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
12.00
12.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/A
Bionomics Limited stock logo
BNOEF
Bionomics
N/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
79.91%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%

Insider Ownership

CompanyInsider Ownership
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/A
Bionomics Limited stock logo
BNOEF
Bionomics
N/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
14.03%
Rezolute, Inc. stock logo
RZLT
Rezolute
18.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/ANot Optionable
Bionomics Limited stock logo
BNOEF
Bionomics
N/A1.31 billionN/ANot Optionable
Meta Platforms, Inc. stock logo
META
Meta Platforms
67,3172.55 billion2.19 billionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
5740.13 million32.83 millionNot Optionable

BNOEF, BGT, RZLT, META, and TLY Headlines

SourceHeadline
Rezolute (NASDAQ:RZLT) Now Covered by JonestradingRezolute (NASDAQ:RZLT) Now Covered by Jonestrading
americanbankingnews.com - April 20 at 4:42 AM
Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by JMP SecuritiesRezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by JMP Securities
americanbankingnews.com - April 20 at 1:54 AM
JonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy Recommendation
msn.com - April 19 at 8:15 AM
Rezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP SecuritiesRezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP Securities
marketbeat.com - April 18 at 2:21 PM
Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)
marketbeat.com - April 18 at 8:35 AM
Optimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment ProspectsOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospects
markets.businessinsider.com - April 18 at 5:30 AM
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
investorplace.com - April 15 at 3:43 PM
Rezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, PredictionsRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictions
benzinga.com - April 10 at 4:10 PM
Rezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim GroupRezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim Group
marketbeat.com - April 9 at 8:23 AM
Insiders Are Buying These 5 Penny StocksInsiders Are Buying These 5 Penny Stocks
insidermonkey.com - April 4 at 8:51 AM
Rezolute, Inc. (NASDAQ:RZLT) Short Interest UpdateRezolute, Inc. (NASDAQ:RZLT) Short Interest Update
marketbeat.com - March 27 at 9:30 PM
Rezolute Reaches US$75m Market Cap Benefiting Insider Stock BuyingRezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying
finance.yahoo.com - March 27 at 8:51 AM
3 Stocks Insiders Are Buying That Analysts Love (RZLT)3 Stocks Insiders Are Buying That Analysts Love (RZLT)
insidertrades.com - March 26 at 12:55 PM
Rezolutes chief medical officer buys $18.8k in company stockRezolute's chief medical officer buys $18.8k in company stock
investing.com - March 20 at 5:29 PM
Daron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockDaron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock
insidertrades.com - March 20 at 7:32 AM
Brian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockBrian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock
insidertrades.com - March 19 at 5:40 AM
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of StockInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of Stock
insidertrades.com - March 15 at 11:42 AM
Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in StockRezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in Stock
insidertrades.com - March 11 at 7:22 AM
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
globenewswire.com - March 6 at 7:30 AM
Rezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning CallsRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Calls
benzinga.com - February 22 at 12:13 PM
Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
finanznachrichten.de - February 16 at 9:03 AM
Were Keeping An Eye On Rezolutes (NASDAQ:RZLT) Cash Burn RateWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
finance.yahoo.com - February 15 at 7:59 AM
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
finance.yahoo.com - February 13 at 7:04 PM
Buy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic EfficacyBuy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic Efficacy
markets.businessinsider.com - February 8 at 8:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BlackRock Floating Rate Income Trust logo

BlackRock Floating Rate Income Trust

NYSE:BGT
BlackRock Floating Rate Income Trust is a close ended fixed income mutual fund launched by BlackRoack Inc. The fund is co-managed by BlackRock Advisors, LLC and BlackRock Financial Management, Inc. It invests in the fixed income markets across the globe while focusing on the United States. The fund invests in bonds of companies operating across diversified sectors. It invests in corporate bonds with average effective duration of its portfolio will be no more than 1.5 years. The fund was formerly known as BlackRock Global Floating Rate Income Trust. BlackRock Floating Rate Income Trust was formed on August 30, 2004 and is domiciled in the United States.
Bionomics logo

Bionomics

OTCMKTS:BNOEF
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Meta Platforms logo

Meta Platforms

NASDAQ:META
Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California
Rezolute logo

Rezolute

NASDAQ:RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.